Very long-term efficacy of venetoclax combined with hypomethylating agents in two AML elderly: is it the time for treatment discontinuation strategies?

Ann Hematol. 2024 May;103(5):1787-1788. doi: 10.1007/s00277-024-05700-4. Epub 2024 Mar 9.

Authors

Pasquale Niscola¹, Valentina Gianfelici², Marco Giovannini², Daniela Piccioni², Carla Mazzone², Paolo de Fabritiis²

Affiliations

¹ Hematology Unit, Sant 'Eugenio Hospital of Rome, ASL Roma 2, Rome, Italy. pniscola@gmail.com.
² Hematology Unit, Sant 'Eugenio Hospital of Rome, ASL Roma 2, Rome, Italy.

PMID: 38459155
DOI: 10.1007/s00277-024-05700-4

No abstract available

Publication types

Letter

MeSH terms

Aged
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Azacitidine* / therapeutic use
Bridged Bicyclo Compounds, Heterocyclic / therapeutic use
Decitabine / therapeutic use
Humans
Leukemia, Myeloid, Acute* / drug therapy
Leukemia, Myeloid, Acute* / genetics
Sulfonamides*

Substances

venetoclax
Decitabine
Azacitidine
Bridged Bicyclo Compounds, Heterocyclic
Sulfonamides